An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure

Trial Profile

An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs Volasertib (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 Dec 2016 Status changed from recruiting to discontinued.
    • 06 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
    • 06 Sep 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top